Holen Sie sich die Stockscreener-App
54.22
1.88%
-1.04
Handel nachbörslich:
54.35
0.13
+0.24%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$55.26
Offen:
$54.52
24-Stunden-Volumen:
15.33M
Relative Volume:
1.02
Marktkapitalisierung:
$110.38B
Einnahmen:
$48.03B
Nettoeinkommen (Verlust:
$6.05B
KGV:
18.31
EPS:
2.9615
Netto-Cashflow:
$15.30B
1W Leistung:
-3.04%
1M Leistung:
+0.06%
6M Leistung:
+14.48%
1J Leistung:
-3.68%
1-Tages-Spanne:
$53.88
$54.91
1-Wochen-Bereich:
$53.88
$57.04
52-Wochen-Spanne:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
54.22 | 112.50B | 48.03B | 6.05B | 15.30B | 2.9615 |
|
LLY
Lilly Eli Co
|
1,041.29 | 929.39B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.21 | 526.82B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
214.04 | 378.84B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
143.58 | 276.96B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
109.45 | 270.12B | 63.90B | 19.05B | 13.05B | 7.5596 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-12-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Bristol Myers (BMY) Teams Up with Microsoft for Lung Cancer Dete - GuruFocus
Bristol-Myers Squibb (BMY) Upgraded to Buy by UBS, Noting a Skewed Risk/Reward Ratio for the Stock - Yahoo Finance UK
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now? - TradingView — Track All Markets
Bristol Myers, Microsoft Aim To Catch Lung Cancer Early With New AI Tool - Benzinga
Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035 - Yahoo Finance
Microsoft (MSFT) and Bristol Myers Squibb (BMY) Partner to Enhan - GuruFocus
Bristol Myers partners with Microsoft for AI-driven lung cancer detection - Reuters
Guggenheim Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $62 - 富途资讯
Bristol Myers partners with Microsoft for AI-driven lung cancer detection By Reuters - Investing.com
Bristol Myers Squibb Partners With Microsoft On AI Lung Cancer Detection - Nasdaq
Bristol Myers Squibb and Microsoft partner to detect lung cancer earlier - Investing.com
Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026 - Finviz
2 Dividend Stocks to Buy and Hold For 10 Years - Finviz
Syngene expands research collaboration with Bristol Myers Squibb - The Economic Times
Immunai and Bristol Myers Squibb sign AI partnership - jpost.com
Syngene extends Bristol Myers Squibb research partnership till 2035 - scanx.trade
Syngene International Extends Research Partnership With Bristol Myers Squibb Through 2035 - scanx.trade
Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock With a Path to Growth - Chartmill
2 Top Blue-Chip Stocks to Buy and Hold in 2026 - morningstar.com
How Is The Market Feeling About Bristol-Myers Squibb Co? - Benzinga
Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai - Endpoints News
Another ADC foray for Bristol Myers Squibb - The Pharma Letter
Campbell & CO Investment Adviser LLC Has $5.81 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
The Bull Case For Bristol-Myers Squibb (BMY) Could Change Following Camzyos’ Phase 3 Adolescent oHCM Win - simplywall.st
Bernstein Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY) - The Globe and Mail
Immunai and Bristol Myers Squibb turn to AI to decode immune responses in clinical trials - CTech
Stephens Inc. AR Raises Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (NYSE:BMY) Trading 1.9% Higher After Analyst Upgrade - MarketBeat
Rep. Gilbert Ray Cisneros, Jr. Buys Bristol Myers Squibb Company (NYSE:BMY) Shares - MarketBeat
Bristol-Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent Patients - Finviz
Bristol Says New Version of Opdivo on Track to Meet Target - Bloomberg.com
Leerink Partners Remains a Buy on Bristol-Myers Squibb (BMY) - The Globe and Mail
Manning & Napier Advisors LLC Lowers Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Pharmaceutical research and development pipeline - Bristol Myers Squibb
Leerink Partners Raises Price Target for Bristol-Myers Squibb (BMY) to $60 | BMY Stock News - GuruFocus
Leerink Partners Issues Positive Forecast for Bristol Myers Squibb (NYSE:BMY) Stock Price - MarketBeat
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock - Yahoo Finance
Bristol Myers Squibb Company $BMY Position Raised by Sumitomo Mitsui Trust Group Inc. - MarketBeat
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff - Pharmaceutical Technology
Bristol-Myers Squibb stock price target raised to $60 from $54 at Leerink - Investing.com
Bristol Myers Squibb Company $BMY Shares Sold by GRIMES & Co WEALTH MANAGEMENT LLC - MarketBeat
Worldwide locations - Bristol Myers Squibb
JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year - BioPharma Dive
AbbVie Becomes Latest To License PD-1xVEGF Bispecific In Growing Field - Citeline News & Insights
JPM26: Bristol Myers CEO to 'cast a broad net' as business development remains a top priority - Fierce Pharma
Scotiabank Raises Bristol-Myers (BMY) PT to $60 Citing Catalyst-Rich 2026 Growth - Finviz
Bristol Myers Squibb CEO Outlines 2030 Growth Strategy Focused on Oncology, Immunology, and Cardiovascular Expansion at JP Morgan Healthcare Conference - geneonline.com
Bristol-Myers Squibb Stock Under Pressure: Is This Deep-Value Pharma Name Finally Near a Turning Poi - AD HOC NEWS
Bristol-Myers Squibb Company (BMY) Releases New Investor Presentation - GuruFocus
Bristol-Myers Squibb Advances Liver Cancer Combo as Key Trial Reaches Completion - TipRanks
What You Need To Know Ahead of Bristol-Myers Squibb's Earnings Release - Barchart.com
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
0.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):